Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

3.440 -0.210 (-5.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 185,788
Open 3.690
Bid (Size) 3.240 (50)
Ask (Size) 3.700 (5)
Prev. Close 3.650
Today's Range 3.160 - 3.930
52wk Range 0.8442 - 6.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Via ACCESSWIRE

Performance

YTD
+166.67%
+166.67%
1 Month
+1.47%
+1.47%
3 Month
-9.71%
-9.71%
6 Month
-23.21%
-23.21%
1 Year
+262.11%
+262.11%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
First Results from Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Results from Lexaria's Molecular Characterization Study
Via ACCESSWIRE
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control
Via Investor Brand Network
Topics Animal Testing Intellectual Property
Exposures Animal Testing Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
Via CannabisNewsWire
Topics Regulatory Compliance
Exposures Legal Regulatory
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study Program
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Recent Animal Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
Via CannabisNewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.